1040 related articles for article (PubMed ID: 30404654)
1. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.
Makani V; Zhang B; Han H; Yao Y; Lassalas P; Lou K; Paterson I; Lee VM; Trojanowski JQ; Ballatore C; Smith AB; Brunden KR
Acta Neuropathol Commun; 2016 Sep; 4(1):106. PubMed ID: 27687527
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
[TBL] [Abstract][Full Text] [Related]
4. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
[TBL] [Abstract][Full Text] [Related]
5. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
[TBL] [Abstract][Full Text] [Related]
6. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR
J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084
[TBL] [Abstract][Full Text] [Related]
7. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
[TBL] [Abstract][Full Text] [Related]
8. Correction of microtubule defects within Aβ plaque-associated dystrophic axons results in lowered Aβ release and plaque deposition.
Yao Y; Nzou G; Alle T; Tsering W; Maimaiti S; Trojanowski JQ; Lee VM; Ballatore C; Brunden KR
Alzheimers Dement; 2020 Oct; 16(10):1345-1357. PubMed ID: 32918367
[TBL] [Abstract][Full Text] [Related]
9. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
[TBL] [Abstract][Full Text] [Related]
10. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.
Zhang B; Maiti A; Shively S; Lakhani F; McDonald-Jones G; Bruce J; Lee EB; Xie SX; Joyce S; Li C; Toleikis PM; Lee VM; Trojanowski JQ
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):227-31. PubMed ID: 15615853
[TBL] [Abstract][Full Text] [Related]
11. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
[TBL] [Abstract][Full Text] [Related]
12. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease.
Chiasseu M; Alarcon-Martinez L; Belforte N; Quintero H; Dotigny F; Destroismaisons L; Vande Velde C; Panayi F; Louis C; Di Polo A
Mol Neurodegener; 2017 Aug; 12(1):58. PubMed ID: 28774322
[TBL] [Abstract][Full Text] [Related]
13. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.
Barten DM; Fanara P; Andorfer C; Hoque N; Wong PY; Husted KH; Cadelina GW; Decarr LB; Yang L; Liu V; Fessler C; Protassio J; Riff T; Turner H; Janus CG; Sankaranarayanan S; Polson C; Meredith JE; Gray G; Hanna A; Olson RE; Kim SH; Vite GD; Lee FY; Albright CF
J Neurosci; 2012 May; 32(21):7137-45. PubMed ID: 22623658
[TBL] [Abstract][Full Text] [Related]
14. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
Ivashko-Pachima Y; Maor-Nof M; Gozes I
PLoS One; 2019; 14(3):e0213666. PubMed ID: 30865715
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
16. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341
[TBL] [Abstract][Full Text] [Related]
17. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
Ivashko-Pachima Y; Gozes I
Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943
[TBL] [Abstract][Full Text] [Related]
18. Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo.
Planel E; Krishnamurthy P; Miyasaka T; Liu L; Herman M; Kumar A; Bretteville A; Figueroa HY; Yu WH; Whittington RA; Davies P; Takashima A; Nixon RA; Duff KE
J Neurosci; 2008 Nov; 28(48):12798-807. PubMed ID: 19036972
[TBL] [Abstract][Full Text] [Related]
19. Tau and axonopathy in neurodegenerative disorders.
Higuchi M; Lee VM; Trojanowski JQ
Neuromolecular Med; 2002; 2(2):131-50. PubMed ID: 12428808
[TBL] [Abstract][Full Text] [Related]
20. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y; Jouroukhin Y; Gray AJ; Ma L; Hirata-Fukae C; Li HF; Feng L; Lecanu L; Walker BR; Planel E; Arancio O; Gozes I; Aisen PS
J Pharmacol Exp Ther; 2008 Apr; 325(1):146-53. PubMed ID: 18199809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
